Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
John Wiley & Sons, Inc.
Wiley publishes scientific journals and educational content that researchers, students, and professionals pay to read and use.
Wiley is one of the world's oldest publishers, and its business today is knowledge — mostly the kind that comes with footnotes. It publishes hundreds of scientific, technical, and medical journals, the places where researchers announce new findings and, crucially, where other researchers go to check what has already been proven. It also sells learning materials: textbooks, courseware, and digital study tools for students and professionals. Most people meet Wiley through a journal article behind a paywall or a textbook assigned in class, but the real customers are often institutions — university libraries, research funders, and companies that pay subscription fees so their people can read the work.
The journal business runs on a peculiar economic engine. Researchers write the papers, other researchers review them for free, and then libraries pay Wiley for access — which means Wiley earns money without paying for the content it sells. That model has made academic publishing enormously profitable for decades, and it is also why it draws fierce criticism. Universities and funders have pushed back hard against rising subscription costs, and the movement toward "open access" — where authors or their institutions pay a fee so anyone can read the paper for free — has reshaped the industry. Wiley has leaned into that shift rather than fighting it, striking open-access agreements with major research bodies and buying up publishing assets to grow its share of the market. Its biggest recent bet was buying Hindawi, a fast-growing open-access publisher, for roughly $300 million in 2021 — a deal meant to supercharge Wiley's open-access revenue. It worked at first, then went badly wrong: a wave of fraudulent or compromised papers slipped through Hindawi's peer-review process, forcing Wiley to suspend special issues, pull thousands of articles, and take a sizable financial hit. That mess is a useful reminder that Wiley's real product is trust. If researchers stop believing a journal vets papers properly, the subscription money eventually follows. Wiley isn't the only giant in this space. It competes for authors and library budgets with RELX, whose Elsevier unit is the biggest scientific publisher, and with Springer Nature — though Springer Nature trades thinly and its listing status has been unsettled, so treat it as a competitor first and a stock second. Wiley's edge is breadth: it spans journals, textbooks, and professional certification materials, giving it many ways to sell to the same institutions. Its vulnerability is that same institutional customer base, which is under budget pressure and increasingly demanding that research be free to read.
The company is a steady cash generator but not a fast grower, and it has spent recent years slimming down — selling off assets and cutting costs to focus on research publishing and learning. It pays a dividend that has made it a favorite of income-focused investors, though the payout has been under strain as the Hindawi cleanup and softer demand weighed on results. Wiley is, in the end, a business built on a simple proposition: someone did the research, and someone else needs to find it. As long as that remains true, there is money in being the place where it gets published.
Saved answer · last researched 14 Nov 2026